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Recommendations for myeloid-derived suppressor
cell nomenclature and characterization standards
Vincenzo Bronte1,*, Sven Brandau2, Shu-Hsia Chen3, Mario P. Colombo4,
Alan B. Frey5, Tim F. Greten6, Susanna Mandruzzato7,8, Peter J. Murray9,
Augusto Ochoa10, Suzanne Ostrand-Rosenberg11, Paulo C. Rodriguez12,
Antonio Sica13,14, Viktor Umansky15,16, Robert H. Vonderheide17
& Dmitry I. Gabrilovich18,*
Myeloid-derived suppressor cells (MDSCs) have emerged as major regulators of immune
responses in cancer and other pathological conditions. In recent years, ample evidence
supports key contributions of MDSC to tumour progression through both immune-mediated
mechanisms and those not directly associated with immune suppression. MDSC are the
subject of intensive research with 4500 papers published in 2015 alone. However, the
phenotypic, morphological and functional heterogeneity of these cells generates confusion in
investigation and analysis of their roles in inﬂammatory responses. The purpose of this com-
munication is to suggest characterization standards in the burgeoning ﬁeld of MDSC research.
Deﬁnition of MDSC
A
t steady-state, myelopoiesis is a structured process where progeny of common precursors
acquire speciﬁc markers and functions of circulating leucocytes, and in doing so
progressively lose the ability to self-renew. The turnover of mature leucocytes is
substantial, with billions of cells generated and replaced daily. A variety of pathological conditions
can perturb the steady supply of leucocytes resulting in emergency myelopoiesis1, which serves to
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provide cells to eliminate potential threats, either abnormal cellular
growth (cancer), infectious agents or tissue damage. If these
conditions resolve quickly, the balance of myeloid cells is restored
without negative consequences for the host. However, a number of
conditions associated with various types of chronic inﬂammation,
autoimmune diseases and cancer results in aberrant, sustained
myelopoiesis characterized by the accumulation of immature
myeloid cells that deviate from the standard path of differentiation.
These cells are distinct from mature, terminally differentiated
myeloid cells (macrophage, dendritic cells or neutrophils) and have
an activation programme (pathologic activation), which is different
from that of mature myeloid cells.
Early studies on inﬂammation in the mouse highlighted a
shared, systemic expansion of myeloid cells bearing the
markers CD11b (CR3A or integrin aM) and Gr-1 (anti-Gr-1
mAbs recognize epitopes common to Ly6C and Ly6G) (refs 2–5).
It became apparent that CD11bþGr-1þ cells were heterogeneous,
which generated uncertainty in description of these cells among
different groups of investigators, an ambiguity ampliﬁed by the use
of different acronyms to deﬁne these cells. In an attempt to
codify analysis of the nature and clinical signiﬁcance of these
cells, 9 years ago a group of investigators suggested to utilize the
term of ‘myeloid-derived suppressor cells’ (MDSC), informed by
the myeloid origin, the immune-suppressive function and the
systemic expansion of MDSC in a cancer-related context6. The
initial intent to introduce MDSC nomenclature was not to deﬁne a
novel population of myeloid cells (at that point being clear that
MDSC are not a distinct myeloid lineage), but to provide a term
that captured the function, origin and heterogeneity of the cells
and offered a framework to guide studies on these remarkable
players in tumour-dependent immune dysfunction.
Since the inception of this term, interest in MDSC has
blossomed. MDSCs are implicated in various aspects of
immune regulation in diseases that involve chronic inﬂammation,
especially cancer, but also infection, autoimmune diseases,
trauma, graft versus host disease and so on. Recently, evidence
of the clinical signiﬁcance of MDSC in cancer has emerged.
Therefore, despite realization that the term ‘MDSC’ may not be
optimal, we feel that it is purposeful and should be retained to
assure consistency as the ﬁeld continues to develop.
However, several notions about MDSC now require reassessment.
First, the cellular nature of MDSC is now better deﬁned and includes
two major subsets based on their phenotypic and morphological
features: polymorphonuclear (PMN) and monocytic (M)-MDSC,
and to reﬂect those discoveries, the terms PMN-MDSC and
M-MDSC were introduced7,8. Initially we and others used the term
‘granulocytic MDSC’ to describe PMN-MDSC, but now we believe
that the latter term better deﬁnes this MDSC subset, since
PMN-MDSC are phenotypically distinct from steady-state
neutrophils (having less granules, altered buoyancy, reduced CD16
and CD62L, and increased arginase 1, peroxynitrite, CD11b and
CD66b) (refs 9,10). It is apparent now that PMN-MDSC and
M-MDSC are not only phenotypically and morphologically distinct,
but also have unique (although partially overlapping) functional
characteristics and biochemical traits, which reﬂect their different
roles under various pathological conditions. Therefore, we believe
that the deﬁnition of MDSC in scientiﬁc reporting needs to include
the speciﬁc subset of MDSCs under investigation.
Second, even though functional analyses of immunoregulatory
activity are often lacking for practical reasons (typically relating to
the paucity of MDSC in human samples), the systemic expansion
of circulating myeloid cells and the correlation with clinical
outcomes have been reported for both solid and hematologic
human malignancies, conﬁrming the concept that tumours
can inﬂuence, at different stages, the ‘distant’ hematopoietic
compartment11,12. The recent identiﬁcation of specialized
molecular programs that orchestrate MDSC differentiation,
joined with high-throughput technologies (see below), has
provided new insight in the multifaceted and unique myeloid
cell development leading to MDSC generation.
The marked growth of publications over the last years has led
to deviation from the original intent of the MDSC nomenclature.
The objective of this review article is not to provide a
comprehensive analysis of the MDSC biology, which has been
done in many recent publications, but to suggest minimal
phenotypic, molecular and functional criteria for reporting
and classifying MDSCs. We also propose to integrate the
increasing observations, in which expansion of cells with MDSC
morphology, phenotype and main biochemical features is not
accompanied by immune suppression. The criteria for deﬁning
cells as MDSCs should include phenotypic and functional, and, if
possible, molecular characteristics described below.
Phenotypic markers to deﬁne MDSC
In mice, MDSCs historically were deﬁned as cells expressing both
Gr-1 and CD11b markers. Although initially useful in identifying
MDSC, the use of this original criterion is no longer sufﬁcient
since subpopulations have been shown to exist: PMN-MDSC
(CD11bþLy6GþLy6Clo) and M-MDSC (CD11bþLy6G
Ly6Chi). Example of staining is provided in Fig. 1. These
cell-surface markers provide only an initial framework for
characterization and can be complemented by various other
markers (described in detail elsewhere)13,14.
In human peripheral blood mononuclear cell (PBMC), the
equivalent to PMN-MDSC are deﬁned as CD11bþCD14
CD15þ or CD11bþCD14CD66bþ and M-MDSC as CD11bþ
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Figure 1 | Gating strategy for the identiﬁcation of mouse MDSC subsets.
Gating strategy used to deﬁne MDSC subpopulations in BM, blood and
spleen of C57Bl/6 tumour-free or MCA203 tumour-bearing mice. After
exclusion of doublets (not shown), live CD11bþ cells were gated and the
proportion of Ly6C and Ly6G cells was evaluated.
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CD14þHLA-DR /loCD15 . CD33 myeloid marker can be used
instead of CD11b since very few CD15þ cells are CD11b .
While M-MDSC express the myeloid marker CD33, PMN-MDSC
display CD33dim staining15. Lin (including CD3, CD14, CD15,
CD19, CD56) HLA-DRCD33þ cells contain mixed groups of
MDSC comprising more immature progenitors. These cells have
been deﬁned as immature MDSC and the mouse equivalent is yet
to be identiﬁed. However, since some immaturity is a common
trait of all MDSC subsets, we propose to deﬁne them more
properly as ‘early-stage MDSC’ (eMDSC). At this point, it appears
that any characterization of MDSC needs to include each of
these cell populations (Table 1). Example of staining is provided
in Fig. 2. A recent report based on the experience of many
laboratories around the world, suggested speciﬁc gating
parameters for harmonized phenotyping of human MDSC by
ﬂow cytometry16. Although various additional populations of
myeloid cells were described in that analysis, their morphological,
biochemical or functional distinctions from each other and from
PMN-MDSC, M-MDSC or eMDSC are not yet clear. In contrast
to the three main populations, which are found (at various
frequencies) in all types of cancer and every pathological
condition, some of those cells may exist in one type of cancer
but absent in the other. It is likely that there is a substantial
overlap between cells belonging to different subsets. Therefore,
more detailed analysis of MDSC populations is needed for
better characterization. However, the minimum (and currently
sufﬁcient) requirements for deﬁnition and characterization of
human MDSCs (PMN-MDSCs, M-MDSCs or eMDSCs)
according to the phenotypic criteria are described in Table 1.
Detailed discussion of the speciﬁc gating criteria for phenotyping
of mouse and human MDSC can be also found elsewhere17.
These gating criteria cannot discriminate monocytes from
M-MDSCs and neutrophils from PMN-MDSC since at present
there are no combinations of markers unique to MDSC.
Presently, the only method allowing for separation of
neutrophils from PMN-MDSC is gradient centrifugation using
1.077 g l 1 density (standard Ficoll gradient used for the isolation
of mononuclear cells). PMN-MDSC are enriched in low density
(mononuclear cell fraction), whereas neutrophils are high-density
cells15. The limitations of this approach are unavoidable.
Low-density fraction contains not only PMN-MDSC, but some
activated neutrophils and probably some PMN-MDSC can pass
through gradient and contaminate high-density fraction of
neutrophils. Therefore, CD11bþCD14CD15þ /CD66bþ cells
in low-density fraction contain both PMN-MDSC and
neutrophils. These cells are heterogeneous in their morphology
(containing both mature and immature cells)18. Since functional,
biochemical and genomic characterization is performed on entire
population of cells, and single-cell functional analysis is not yet
feasible, the precise nature of PMN-MDSC remains unclear. An
important goal for future studies is to deﬁne cell-surface markers
and gating strategies that uniquely identify the different
populations of MDSC. One of the most pressing unmet issues
is to determine markers of MDSC that would allow detection of
cells in unseparated peripheral blood.
It is important to emphasize that the method for collecting and
analysing MDSC can inﬂuence the results: freezing of samples
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Figure 2 | Gating strategy for the identiﬁcation of MDSC subsets in the
peripheral blood of healthy donors and melanoma patients. Doublets were
excluded and live PBMC were gated (not shown). (a) CD14þHLA-DR /lo
M-MDSC. Monocytes were gated on the basis of FSC and SSC parameters
and HLA-DR downregulation was deﬁned by FMO control. (b) LinHLA-
DRCD33þ eMDSC. (c) CD14CD15þCD11bþ PMN-MDSC.
Table 1 | Minimal phenotypic characteristics necessary to identify cells as MDSC.
Mouse Phenotype Human (in PBMC fraction) Phenotype
Total MDSC (not sufﬁcient for MDSC characterization) Gr-1þCD11bþ Total (mixed) MDSC Not clearly determined
PMN-MDSC CD11bþLy6CloLy6Gþ PMN-MDSC CD14CD11bþCD15þ (or CD66bþ )
M-MDSC CD11bþLy6ChiLy6G M-MDSC CD11bþCD14þHLA-DRlow/ CD15
eMDSC Not clearly determined e-MDSC Lin (CD3/14/15/19/56)/
HLA-DR/CD33þ
eMDSC, early-stage MDSC; MDSC, myeloid-derived suppressor cell; M-MDSC, monocytic-MDSC; PBMC, peripheral blood mononuclear cell; PMN-MDSC; polymorphonuclear-MDSC.
Although phenotype is the ﬁrst necessary step for deﬁning MDSC, please note that, it cannot be used as the sole parameter for distinction between PMN-MDSC and neutrophils and M-MDSC and
monocytes.
It is important, wherever possible, to use cells from control mice or healthy donors as controls.
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lead to substantial loss of cells, especially PMN-MDSC19, and
thus comparison with freshly isolated cells is necessary.
Furthermore, one of the main challenges in the ﬁeld is the
phenotypic characterization of MDSC in tissues by immuno-
histochemistry without isolation and functional characterization
of the cells. In mice, Gr-1 or Ly6G staining is used to
identify tumour-associated MDSC. However, the distinction
between neutrophils or monocytes and MDSC in frozen or
parafﬁn-embedded tissues is impossible. In human samples
similar confusion of MDSC with monocytes and neutrophils
exists. Similarly, CD33, a myeloid marker that sometimes is used
for identiﬁcation of MDSC, does not allow for distinction of
MDSC from macrophages, dendritic cells or other myeloid cells
in tissues. Recently, a combination of CD33 with S100A9 was
suggested to identify MDSCs20. However, although this pair of
markers excludes most dendritic cells and macrophages (due to
their low expression of S100A9), it does not permit a clear
distinction of MDSC from neutrophils. Thus, at this moment,
clear phenotypic characterization of human and mouse MDSC by
immunohistochemistry is lacking.
It is important to emphasize that phenotypic evaluation is a
starting point for the analysis of MDSC (see the proposed
algorithm below) since it deﬁnes population of cells in both naive
and pathologically changed hosts. However, expansion of myeloid
compartment under pathologic conditions is a critical, ﬁrst step
that allow for further evaluation of MDSC. For instance, in
healthy donor cells with typical PMN-MDSC phenotype in the
peripheral blood mononuclear cell fraction are practically
undetectable and cells with M-MDSC phenotype are present in
much smaller numbers than in patients with either melanoma or
chronic infections11. In mice, similar situation exists in spleen.
The proportion of splenic MDSCs increases from 1–2% in naive
mice to 10–15% or more in many cancers. In bone marrow and
peripheral blood of mice the differences in the proportion of the
cells are smaller (usually increase is otwofold) (refs 8,21).
Functional assays to deﬁne MDSC
The ability to suppress immune cells is an important characteristic
of MDSC. Although MDSC were implicated in suppression of
different cells of the immune system such as NK and B cells22–24,
inhibition of T cells is the ‘gold’ standard for evaluation of MDSC
function and inhibition of T-cell activity appears to be sufﬁcient
for designation of cells as MDSC, provided that they meet the
phenotypic criteria described above. Different methods for the
evaluation of T-cell suppression are used in the literature
(summarized in Table 2) and can be divided into two groups.
One method assesses antigen-speciﬁc suppression and utilizes
antigen-speciﬁc T cells, activated with cognate peptides or in
an allogeneic mixed leucocyte reaction (MLR), in the presence
of titrated numbers of puriﬁed input MDSC. The second,
non-speciﬁc suppression, uses T cells activated by CD3 antibody,
alone or in combination with CD28 (immobilized or presented
by APC), or with lectins (ConA in mice or PHA in humans,
although an inﬂuence of lectins on other cell types contained in the
in vitro assay is a concern for potential technical biases).
However, antigen-speciﬁc suppression assays are preferable when
possible, since these assays are likely more relevant to in vivo
conditions. Various methods have been used to determine T-cell
function activity modulated by MDSC. Measurement of T-cell
proliferation (either with 3H-thymidine incorporation or by
CFSE dilution) or inhibition of interferon (IFN)-g production
(ELISPOT or intracellular staining) provides experimental
evidence supporting functions associated with MDSC. It is
important to note that, under some experimental conditions,
MDSC could cause inhibition of T-cell proliferation without
affecting IFN-g production and vice versa. The titration of input
MDSC numbers in these tests (and the cognate loss of suppression
as the cells are titrated down) is a critical experimental tool to help
eliminating the possibility of artefacts due to MDSC viability and
to aid in comparison between experiments. One of the critical
issues to consider is the use of appropriate controls—cells with the
same phenotype and preferably from the same tissues from either
healthy donors or naive mice. It is important to point out that
there are several exceptions since neutrophils (cells with the
phenotype similar to PMN-MDSC) are rarely present in the PBMC
fraction of healthy donors. In contrast to PMN-MDSC from
tumour-bearing mice and cancer patients, neutrophils are largely
absent from lymph nodes of naive mice and healthy donors.
The evaluation of tolerogenic activity of MDSC in vivo by
using adoptive transfer of MDSC and antigen-speciﬁc T cells
to syngeneic recipients, with subsequent stimulation of
antigen-speciﬁc T cells with cognate peptide, provides the most
comprehensive way to study different pathways of MDSC activity.
Table 2 | Minimal functional characteristics necessary to identify cells as MDSC.
Mouse functional tests Human functional tests
Type of immune response Assays Autologous system Allogeneic system
 Inhibition of antigen-non-speciﬁc
function (anti-CD3/CD28 or ConA
induced)
 Inhibition of antigen-speciﬁc function
using antigen-speciﬁc T cells (induced
after immunization with peptides or
from transgenic mice)
 Inhibition of 3H-
thymidine
incorporation or
CFSE dilution
 Inhibition of CTL
activity
 Inhibition of IFN-g
production by T cells
in ELISPOT or
intracellular staining
 Inhibition of
expression of CD3z
chain on T cells
 Inhibition of IL-2
production
 Inhibition of anti-CD3/CD28 (or PHA)
induced T-cell proliferation or IFN-g
production (in ELISPOT or by intracellular
staining) by the addition of candidate
MDSC populations
 Improved T-cell proliferation after
removal of candidate MDSC populations
 Inhibition of proliferation or IFN-g
production by T cells (in ELISA, ELISPOTor
by intracellular staining) by the addition of
selected MDSC populations
CTL, cytotoxic T lymphocyte; ELISA, enzyme-linked immunosorbent assay; IFN, interferon; IL, interleukin; MDSC, myeloid-derived suppressor cell.
It is important, wherever possible, to use cells from control mice or healthy donors as controls.
For either antigen-speciﬁc or antigen-non-speciﬁc response, one assay is usually sufﬁcient.
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However, this method requires considerable effort and probably
is not feasible for routine evaluation of MDSC activity. Examples
of the in vivo tolerogenic use of MDSCs could be found in several
publications25,26.
In humans, evaluation of MDSC effects on antigen-speciﬁc
immune responses is difﬁcult due to the limitation in generation
of antigen-speciﬁc T cells. Recent advances allow for transduction
of human T cells with lentiviruses expressing cloned T-cell
receptors, which permits analysis of suppression in antigen-
speciﬁc assays using cognate peptides in the presence of
autologous antigen-presenting cells and MDSC. Currently, a
three-way allogeneic MLR is a reliable method for functional
assessment of human MDSC. This assay utilizes cells obtained
from a pair of unrelated healthy donors: one is the source of
T cells, the other one provides APCs. The pair is selected based on
strong T-cell proliferative or IFN-g responses of the responder,
and aliquots of cells can be stored for use in subsequent iterative
experiments. MDSCs from cancer patients are tested in MLR at
different ratios compared with responder T cells. The assay is
based on the premise that allogeneic MLR requires presentation
of epitopes in the context of MHC class II and class I, so that
suppression of responses reﬂects the ability of MDSC to prevent
antigen-speciﬁc T-cell immune responses27.
Measurement of human antigen-non-speciﬁc suppression of
T-cell responses by MDSC is based on the same principles as in
mice, and utilizes either anti-CD3/CD28 antibody or activation
with lectins. In several studies, evaluation of MDSC activity was
substantiated by antibody-mediated depletion of candidate cells
from PBMC before analysis of T-cell proliferation. Although this
approach is less attractive, due to technical limitations in
complete MDSC removal and the unintended depletion of
non-MDSC that may share cross-reactive cell-surface molecules,
it may provide valuable information about MDSC functional
activity. To provide for better comparison between different
studies, it is very important to include detailed information about
the experimental protocol used for all steps involved in the
puriﬁcation of MDSC. Since some antibodies used for positive
isolation of MDSC may modify function of these cells, it is
preferable (when possible) to use negative-selection approaches.
In any case, it is important to select control groups to account for
possible impact of isolation techniques on MDSC function.
A number of molecules produced by MDSCs have been
implicated in suppression (discussed below) including: arginases,
NO, ROS, IDO, TGFb and PGE2, among others. Although
important for a thorough understanding of MDSC suppressive
mechanism(s), evaluation of their expression cannot substitute
for functional assays. In different settings MDSCs utilize different
mechanisms of suppression and it is difﬁcult to predict which will
be more prevalent. It is also challenging to ascertain what level of
production of any given effector molecule is sufﬁcient for the
MDSC suppressive activity.
Biochemical and molecular characteristics of MDSCs
One of the most controversial aspects of MDSC biology is why
cells with the morphology and phenotype similar to neutrophils
and monocytes should require a designation of PMN-MDSC
and M-MDSC. The main consideration reﬂects the potent
immune-suppressive activity of MDSCs, the basis to deﬁne them
as functionally different from monocytes and neutrophils.
However, in recent years studies have identiﬁed unique
biochemical and molecular characteristics of MDSC, which
demonstrate that they are pathologically activated. Classical
activation of neutrophils and monocytes has evolved to protect
the host from bacteria and viruses, as well as to provide support
for the remodelling of tissues after injury or after resolved
inﬂammation. This activation state is characterized by robust
phagocytosis, respiratory burst activity and release of
pro-inﬂammatory cytokines. Myeloid activation is relatively
short-lived and terminated on cessation of the stimulus.
In contrast, pathological activation is the result of
persistent stimulation of the myeloid compartment with relatively
low-strength signals coming from tumours or sites of
chronic inﬂammation. Myeloid cells generated under these
conditions are poorly phagocytic, produce high levels of
reactive oxygen and nitrogen species, and predominantly anti-
inﬂammatory cytokines9. As a result, these cells are not able to
perform effectively the normal functions of myeloid cells and
acquire potent immune-suppressive potential. Reﬂecting their
potent immunosuppressive character it possible that the main
role of MDSC is in the protection of the host from extensive
tissue damage caused by uncontrolled immune response
associated with unresolved inﬂammation or infection.
Tumours can hijack and amplify this activity to protect
themselves from elimination by the immune system.
Since MDSC are a continuum of cells in different stages of
differentiation, assignment of biochemical and molecular MDSC
markers will depend on presently incompletely deﬁned processes
that govern differentiation stages of altered myelopoiesis, and
some markers might thus be shared by cells with different
phenotypes or with mature activated monocytes or neutrophils.
For example, conversion of monocytes to granulocytes, a
process known as transdifferentiation, occurs in tumour-bearing
but not tumour-free mice28 (or at least not at the same rate).
Analogously, genes contributing to the immune-suppressive
phenotype, normally conﬁned to some cell types under steady
state, might be activated in MDSCs29.
On the basis of mostly mouse studies, four types of molecular
and biochemical parameters are often associated with immune-
suppressive MDSC as opposed to monocytes and neutrophils
(Table 3). (1) Transcription factors and apoptosis regulators; (2) a
signature of pro- and anti-inﬂammatory cytokines and cytokine
receptors; (3) chemoattractants and related receptors affecting
MDSC trafﬁcking; and (4) enzymes and metabolic by-products
contributing to MDSC immune-regulatory functions. Table 3 also
indicates which molecular and biochemical parameters are often
linked with the speciﬁc MDSC populations (considering PMN-
MDSCs, M-MDSCs and total MDSCs). This grouping is not
exhaustive, but is intended to incorporate key and non-redundant
hubs related to MDSC biology. Although numbers of different
parameters are implicated in MDSC biology and may help to
deﬁne a molecular signature of MDSCs, some parameters are
important for the development of the MDSC ﬁeld and, thus, may
help to identify MDSCs (highlighted in Table 3). Several assays
need to be integrated to evaluate these biomarkers, which exploit
gene and protein expression, as well as multiple post-translational
modiﬁcations. Transcription factors may require assessment of
their activity (DNA binding, phosphorylation). Technologies based
on the detection of mRNA translation might be insufﬁcient to
classify MDSC as several mediators of MDSC function are
regulated epigenetically or post-translationally. Epigenetic changes,
such as histone modiﬁcation related to myeloid differentiation, are
an intensively studied and promising area of investigation, and
have the potential to facilitate tracking cell stages during fate
mapping analyses30. However, currently there is no clear
indication about epigenetic markers that can discriminate
speciﬁc MDSC subsets. A similar consideration is valid for
microRNAs, even though in our experience microRNA
signatures can be a useful classiﬁer of myeloid cell subsets under
different pathological conditions31.
A panoply of cytokines can either inﬂuence the properties
and/or are produced by one or more subsets of MDSCs.
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These cytokines may establish an autocrine feed-forward loop
that sustains MDSC accumulation, since they are not only
released during chronic inﬂammation inducing MDSC, but are
also released by MDSC. Chemokines and their receptors might
complement the assessment of the overall inﬂammatory state,
however, no chemokine is truly speciﬁc for MDSCs.
An immune-regulatory activity of MDSCs depends on
the metabolic consumption and conversion of the amino acids
L-arginine and L-tryptophan, by the activity of inducible enzymes
such as arginase 1 (ARG1), nitric oxide synthase 2 (NOS2/iNOS).
Since most available antibodies to these enzymes are fraught with
the lack of speciﬁcity and need to access the intracellular
compartment where their targets are located, detection of
these enzymes is often performed by RT–PCR. However, RNA
and protein levels are not necessarily coincident, and the mere
presence of either RNA or protein does not conﬁrm enzyme
activation. For this reason, biochemical analyses of downstream
metabolites (such as NO, kinurenines, ornithine, urea and
polyamines) might be an alternative assay. MDSCs are also high
producers of soluble reactive species. Reactive oxygen species
exempliﬁed by superoxide anion (O2 ) and peroxide hydrogen
(H2O2), are generated by the activity of NADPH oxidase
(NOX) family members, in which NOX2 is likely active in
myeloid cells. Reactive nitrogen species, such as the free-radical
peroxynitrite (ONOO–), are by-products of the combined
activity of iNOS, ARG1 and NOX, and can induce a number of
detectable covalent alterations in select aromatic amino acids of
proximal proteins by enzyme-independent nitration/nitrosylation
(Table 3). The complexity of the post-translational modiﬁcations
induced by peroxynitrite, the ‘nitrome’, is not fully appreciated
yet, but detection of nitrotyrosine and nitrotryptophan may be
convenient for evaluating overall reactive nitrogen species
production in biological samples, provided that more
effective/speciﬁc antibodies are developed in the future. Finally,
the clinical use of new checkpoint-blockade inhibitors for the
therapy of human cancers, supports evaluation of their ligands
(for example, PD-L1) in MDSCs, whose expression is inﬂuenced
by local environmental factors such as inﬂammatory cytokines or
hypoxia32,33.
MDSC versus tumour-associated macrophages and
neutrophils
Tumours contain a complex landscape of myeloid cells, which is
associated with tumour progression and response to therapy34,35.
However, the speciﬁc role of individual components of this
landscape remains obscure. While the literature on tumour-
associated myeloid cells assigned an unequivocal tumour-
promoting activity to M-MDSCs and PMN-MDSCs12,36, both
tumour-associated macrophages (TAM) and tumour-associated
neutrophils (TAN) can exert either tumour-promoting or anti-
tumour activities in different cancers37,38. This dual capacity stems
out from the apparent phenotypic plasticity of TAM and TAN,
which is modulated through their transcriptional re-programming
operated by distinct micro-environmental signals, at different stages
of tumour progression37–40.
This raises an important question of how to distinguish these
cells. In mice, PMN-MDSC and TAN can be separated from
mononuclear cells within the CD11bþ myeloid cell fraction by
the expression of Ly6G granulocytic cell marker and eosinophils
can be distinguished by the expression of sialic acid-binding
immunoglobulin-like lectin F41,42. Mononuclear cells in tumours
likely exist in various differentiation phases from monocytes/
M-MDSCs towards TAM. Molecularly, this process is
accompanied by the upregulation of anti-apoptotic molecules
cFLIP and A1, as well as the enzyme ARG1 (refs 32,43; Fig. 3).
Table 3 | Biochemical and molecular parameters associated with MDSC characterization.
Class of biomarkers Biomarker Detection technology Mainly found in Reference
Transcription factors and apoptotic regulators k IRF8*
Phospho-STAT3*
cEBP/b*
S100A8/9*
RB
Phospho-STAT5
ROR/RORC1
sXBP, CHOP
FC, P
PTM (FC, ELI), FA
ELI, P, T, FA
ELI, FC, IHC, P, T
IF, P, T, FC
PTM (FC, IHC, P), FA
FC, P
P, T
MDSC
MDSC
MDSC
MDSC
M-MDSC4PMN-MDSC
MDSC
PMN-MDSC
MDSC
56
57–59
26,31
60,61
28w
62
44
46,47
Genes and molecules contributing to the
immune-regulatory activity
ARG1*
NOS2/NO*
NOX2/ROS*
PNT/RNS*
VEGF
PGE2
PD-L1
E, FC, IHC, P, T
FC, IF, IHC, P, T
E, FC, P, T
PTM (IHC), E, FC
FC, IHC
ELI
FC, P, T
M-MDSC
M-MDSC
PMN-MDSC
MDSC
MDSC
M-MDSC
MDSC
63,64
65,64,8,66,46
59,67
27,68,65
69,70
71,72
73
Cytokines and receptors IL-10*
TGFb*
IL-4R (CD124)*
ELI, FC, T
ELI, FC, T, P
FC, T
MDSC
M-MDSC
M-MDSC
74,75
66,76
63,77
Cytokines involved in MDSC development
These cytokines are not produced by MDSC.
However, they are important for the evaluation of
MDSC microenvironment.
GM-CSF
G-CSF
IL-13
IL-1
ELI, T
ELI, T
FC
ELI
MDSC
PMN-MDSC
M-MDSC
MDSC
21,78,79
21,79,80
63,81
22,74,75
E, enzyme assay; ELI, enzyme-linked immunosorbent assay; FA, functional activity (for example, DNA binding); FC, ﬂow cytometry (including ICS, intracellular staining); IF, immunoﬂuorescence;
IHC, immunohistochemistry; IL, interleukin; MDSC, myeloid-derived suppressor cell; M-MDSC, monocytic-MDSC; P, protein detection in cell extracts or supernatants (that is, by western blot, mass
spectrometry); PMN-MDSC; polymorphonuclear-MDSC; PTM, post-translational modiﬁcation; T, transcript analysis (that is, by RT–PCR, RNA-seq or in situ hydridization).
It is important, wherever possible, to use cells from control mice or healthy donors as controls.
PMN-MDSCs are compared with neutrophils and M-MDSCs are compared with monocytes.
Total population of MDSCs in most of these studies was compared with Gr-1þCD11bþ cells from control mice. Characteristics described in the table are the same for MDSC and MDSC-LC.
*Parameters crucial for MDSC biology and, thus, for their identiﬁcation.
wIn this study Rb expression was largely compared between the groups of M-MDSC and PMN-MDSC.
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Phenotypically, TAM can be distinguished from M-MDSCs by
increased relative expression of F4/80, low-to-intermediate
expression of Ly6C and low or undetectable expression of
S100A9 protein. When compared with M-MDSCs, TAM express
higher amounts of IRF8, a marker of terminal macrophage
differentiation, and increased M-CSF receptor, CD115 (ref. 44).
Most of the published data indicate that cells with the phenotype
of inﬂammatory monocytes (CD11bþLy6ChiLy6G ) in tumours
have potent immune-suppressive activity and thus can be
attributed to M-MDSCs45. However, whether this is indeed the
case, can be clariﬁed when speciﬁc markers of M-MDSCs are
identiﬁed. There is evidence that PMN-MDSCs and M-MDSCs
can be distinguished from neutrophils and monocytes due to
their elevated ER stress response46,47.
In the absence of functional tests, the distinction between
neutrophils and PMN-MDSCs is impossible, since these cells
share the same phenotype. This limitation of phenotypical
distinction between PMN-MDSCs and neutrophils only partially
alleviated with additional staining with some antibodies.
Compared with mature neutrophils, some PMN-MDSCs in the
blood/spleen of mice have lower expression of the receptors for Fc
(CD16/CD32) and complement (C5aR) and higher expression of
the transcription factor retinoic-acid-related orphan receptor, an
inhibitor of neutrophil maturation37, In some tumour models,
some PMN-MDSCs, in contrast to neutrophils from naive mice,
may express CD115 and CD244 (ref. 9). However, these markers
have limited direct value for delineation of these cells due to
apparent heterogeneity of PMN-MDSCs. A whole-transcriptomic
analysis provided a pattern of gene expression that allows
for discrimination between spleen PMN-MDSCs from tumour-
bearing mice, and spleen and bone marrow neutrophils from
tumour-free naive mice9,48.
The situation with TAN is different. TAN are a heterogeneous
population of cells with some cells demonstrating pro-tumouri-
genic and some anti-tumour activity38,49. The distinction between
TAN and PMN-MDSCs is currently impossible, since these
cells share the same phenotype. A nomenclature on circulating
neutrophils and TANs was recently suggested based on different
parameters, such as gradient density, morphology function and
tissue localization50. While concepts about cell subsets are certainly
helpful for future discussions, mechanistic evidence about distinct
maturation and differentiation steps involving neutrophils are
still preliminary. For instance, the terms anti-tumourigenic N1
and pro-tumourigenic N2 mouse neutrophils were introduced
to describe different populations of TAN18,38. However, the
phenotype and functional characteristics of N2 neutrophils are
very similar to that of PMN-MDSCs, which necessitate
better characterization of these cells. This notion is supported by
data demonstrating potent immune-suppressive activity by
TAN, which deﬁnes these cells as PMN-MDSCs51–53. A whole-
transcriptomic analysis demonstrated a substantial difference
between TAN and spleen neutrophils and PMN-MDSCs37.
However, the transcriptomic analysis of true tumour
PMN-MDSCs will not be possible until markers separating these
cells from TAN are discovered.
In humans, macrophage-speciﬁc markers CD68 and CD163, as
well as low or absent expression of S100A9 can be used
to discriminate between TAM and tumour M-MDSCs. The
challenges in distinguishing between tumour PMN-MDSCs and
TAN are the same as in mice: no clear cell-surface markers exist
so far to allow for direct separation between TAN and PMN-
MDSCs.
Proposed experimental algorithm for MDSC reporting
Immune-suppressive activity has been long considered as the major
characteristic of MDSCs, and the lack of unique phenotypic
markers made it previously impossible to characterize these cells as
MDSCs if immune-suppressive activity was not detected. These cells
have been referred to as TAN or monocytes38,54, but recently this
designation has been reﬁned. More sophisticated biochemical and
gene-expression proﬁling has allowed for characterization of these
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Figure 3 | Overview of MDSC involvement in myeloid cell differentiation in cancer. In cancer and chronic inﬂammation, the bone marrow and spleen
increase the output of mature and immature myeloid cells that comprise a spectrum between monocytes and neutrophils. In mice, MDSC toward the
monocytic end of the spectrum (M-MDSC) are CD11bþLy6Cþ Ly6G , while towards the neutrophil end of the spectrum (PMN-MDSC) are
CD11bþLyGþLy6C . Within solid tumours M-MDSC develop through intermediate steps towards macrophages where Ly6C is progressively downregulated
and MHCII, F4/80 and CX3CR1 are upregulated. Under chronic inﬂammation, monocytic lineages show an increasing requirement for anti-apoptotic survival
pathways (mediated primarily by GM-CSF signalling) to block the intrinsic mitochondrial death pathway. A similar scheme is likely to occur in humans;
however, the cell markers are different.
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cells as pathologically activated, immature myeloid cells distinct
from myeloid cells found in the steady state. Immune-suppressive
activity, although a critically important attribute of MDSC, is not
always associated with the cells present in tumour-bearing hosts or
in conditions of chronic inﬂammation. For example, early stages
of cancer or initial stages of chronic inﬂammation may be
associated with accumulation of cells with phenotypic (Table 1)
and biochemical characteristics (Table 3) of MDSC but lacking
potent suppressive activity. Moreover, it is possible that even in
advanced-stage cancer, not all cells with a MDSC phenotype
possess immune-suppressive activity. Although the nature of the
factors responsible for acquisition of the immune-suppressive
phenotype of MDSC is not entirely clear, non-suppressive
MDSCs can nonetheless regulate various aspects of tumour onset
and progression5,12,36. In fact, recent studies demonstrated that in
the setting of chronic inﬂammation cells with an MDSC phenotype,
but lacking suppressive activity contribute to the early stages of
tumour inﬂammation20,55. Since the term ‘MDSC’ presumes
suppressive activity, this term should not be used to identify cells
lacking this function. Therefore, when describing these cells we
suggest the term MDSC-like cells (MDSC-LC; Fig. 4).
For deﬁning MDSC populations in mice and humans, we
propose an algorithmic approach that ﬁrst focuses on the
phenotypic characterization of the cells (Table 1). If cells meet
these criteria, then suppressive activity must be determined
(Table 2). The presence of suppressive activity would deﬁne these
cells as MDSC. However, if cells lack suppressive activity, then
major biochemical characteristics of these cells need to be
evaluated (Table 3). On the basis of the available data we suggest
the following criteria that could help to deﬁne MDSC-LC in the
absence of suppressive activity. The analysis should include
appropriate controls: cells with the same phenotype from healthy
individuals or naive mice. These criteria include changes in at
least two critical transcription factors and regulators—such as,
IRF8, phospho-STAT3, c/EBPb, S100A8/A9, Rb1—and
upregulation of at least one critical cytokine/receptor—such as,
IL-10, TGFb, IL-4R—or immune-regulatory molecule—such
as,ARG1, NOS2, NOX2, PNT, PGE2. The number of parameters
can be further expanded as new information becomes available.
The absence of relevant biochemical characteristics would then
exclude these cells as MDSC, whereas the presence of these
markers would allow characterization of these cells as MDSC-LC
(Fig. 4). Deﬁnition of molecular pathways and markers for
MDSC-LC will clarify steps of the differentiation pathway
induced in MDSC by growing tumours and will help to dissect
tumour-promoting functions of MDSC. Furthermore, a better
understanding of the developmental complexity of these cells may
provide additional information on the tumour-promoting
functions of MDSC that either act in a dependent or independent
manner to regulate adaptive and/or innate immunity.
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